Moderna stock has reached day 5 of a consecutive winning streak, with total gains during this time reaching a 13% return.

The first was a one-time stock option exchange program for non-Executive Committee employees, which received significant support from stockholders. The second proposal allowed for the adjournment of ...

MRNA is likely to have faced earnings pressure and pipeline setbacks as waning COVID-19 vaccine demand weighs on its outlook.

There was also a positive sign for investors worried about the rapid pace at which the company has been burning through its ...

Q3 earnings beat estimates but pipeline setback and lower 2025 guidance raise concerns. Full analysis of results and outlook.

In this week's STATus Report, STAT reporters Jason Mast and Damian Garde discuss the challenges facing Moderna — and what could be in store for its third act.

The S&P 500 Healthcare sector (XLV) experienced a slight rise in average short interest during October, moving from 1.91% to ...

Moderna stock is trading sharply lower Monday afternoon as recent clinical setbacks overshadowed positive pipeline news.

Telemark Asset Management, LLC established a new position in Moderna ( MRNA +1.10%), acquiring 500,000 shares valued at approximately $12.91 million as of September 30, 2025, according to a November ...

Moderna (MRNA) stock gains as the company beats Q3 2025 forecasts despite lower COVID vaccine sales and narrows revenue ...

A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled ...

In the past week, Moderna reported third-quarter 2025 earnings with revenue at US$1.02 billion, down sharply from the ...